Table. Comparison of Pretreatment Characteristics between Patients with AML and Mutated DNMT3A or Wild-Type DNMT3A.
| Characteristic | Mutated DNMT3A N=37 |
Wild-Type DNMT3A N=154 |
p-value |
|---|---|---|---|
| Median Age, years (range) | 68 (57-81) | 68 (56-89) | 0.79 |
| Age ≥ 61 years | 12 (32) | 94 (61) | 0.57 |
| Age < 61 years | 25 (68) | 60 (39) | |
| Sex (%) | |||
| Male | 20 (54) | 86 (56) | 0.86 |
| Female | 17 (46) | 68 (44) | |
| ECOG Performance Score | |||
| 0 | 7 (19) | 34 (23) | 0.47 |
| 1 | 20 (54) | 74 (49) | |
| 2 | 8 (22) | 23 (15) | |
| 3 | 2 (5) | 20 (13) | |
| Cytogeneticξ | |||
| Favorable | 0 | 12 (11) | <0.001 |
| Intermediate | 24 (86) | 54 (50) | |
| Unfavorable | 1 (4) | 32 (30) | |
| Unknown* | 3 (11) | 10 (9) | |
| No data | 9 | 46 | |
| Normal cytogenetics (%) | 21 (75) | 45 (42) | 0.003 |
| BM blast (%), median | 70 | 71 | 0.45 |
| WBC ×109/L, median | 37 | 28 | 0.46 |
| Platelet count ×109/L, median | 59 | 60 | 0.61 |
| Hemoglobin (g/dL), median | 9 | 9 | 0.18 |
| FAB subtype (%) | |||
| M0 | 2 (5) | 3 (2) | 0.10 |
| M1 | 9 (24) | 35 (23) | |
| M2 | 6 (16) | 55 (36) | |
| M3 | 0 | 1 (1) | |
| M4 | 10 (27) | 38 (25) | |
| M5 | 7 (19) | 13 (8) | |
| M6 | 0 | 2 (1) | |
| M7 | 0 | 5 (3) | |
| FLT3-ITD present (%) | 13 (35) | 36 (24) | 0.21 |
| NPM1 mutated (%) | 17 (65) | 34 (26) | <0.001 |
| CEBPA mutated (%) | 0 | 3 (2) | 1 |
| IDH1 mutated (%) | 0 | 5 (3) | 0.57 |
| IDH2 mutated (%) | 6 (16) | 34 (22) | |
| Molecular risk group ¥ | |||
| Low risk | 12 (46) | 18 (14) | <0.001 |
| High risk | 14 (54) | 110 (86) |
Abbreviations: AML, acute myeloid leukemia; ECOG, performance status of Eastern Cooperative Oncology Group; FAB, French-American British classification of acute myeloid leukemia; BM, bone marrow; WBC, white blood count.
¥
The high-risk molecular group is defined by the presence of FLT3-ITD Regardless of NPM1 status or the absence of FLT3-ITD and NPM1 wild-type. The low risk group is defined by the absence of FLT3-ITD and NMP1 mutated or CEPBA mutated.
*
Cytogenetic abnormalities of unknown prognostic significance.
ξ
The p-value is from a Fisher's exact test of the cytogenetics categories (favorable, intermediate, unfavorable, unknown) versus DNMT3A status (DNMT3A mutated versus wild-type). Patients with missing data were not included in the test.